Angiogenesis and hematologic malignancy;Angiogenèse et maladies hématologiques

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Zini, Jean Marc ^a   Tobelem, Gérard ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Angiogenesis; Hematologic malignancy

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; VASCULOTROPIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER RELAPSE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; HUMAN; LEUKEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; FIBROBLAST GROWTH FACTOR 2; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; LYMPHOMA; MYELODYSPLASTIC SYNDROMES; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548650251     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0392     Document Type: Review

References (52)

1. Folkman J. Tumor angiogenesis : therapeutic implications. N Engl J Med 1971 ; 285 : 1182-6.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 ; 407 : 249-57.
3. Pezella F, Pastorino U, Tagliabue E, et al. Non small cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am J Pathol 1997 ; 151 : 1417.
4. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro : vasculogenic mimicry. Am J pathol 1999 ; 155 : 739-52.
5. Sharma N. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypes subpopulations : role in vasculogenic mimicry. Prostate 2002 ; 15 : 189.
6. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry an angiogenesis of inflammatory breast cancer xenograft. Cancer Res 2002 ; 62 : 560-6.
7. Schneider P, Vasse M, Shaa-Ketata E, et al. The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis. Leukemia 2001 ; 15 : 1143-5.
8. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1998 ; 86 : 353-64.
9. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995 ; 285 : 1757-63.
10. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992 ; 359 : 843-5.
11. Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptor in hematopoietic malignancies. Cancer Res 1999 ; 59 : 728-33.
12. Fukushima N, Satoh T, Sano M, et al. Angiogenesis and mast cells in non Hodgkin's lymphoma : a strong correlation in angioimmunoblastic T cell lymphoma. Leuk Lymphoma 2001 ; 42 : 709-20.
13. Di Raimondo F, Palumbo GA, Molica S, et al. Angiogenesis in chronic myeloproliferative diseases. Acta Hematol 2001 ; 106 : 177-83.
14. Talks KL, Harris AL. Current status of antiangiogenic factors. Br J Haematol 2000 ; 109 : 477-89.
15. Barleon B, Rusch P, Totzke F, et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes present in human serum and plasma from healthy donors. Angiogenesis 2001 ; 4 : 143-54.
16. Makinen T, Jussila L, Viekkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF-receptor 3. Nat Med 2001 ; 7 : 199-205.
17. Moehler TM, Glodschmidt H, Neben K, et al. Plasma concentration of soluble endothelial specific tyrosine kinase receptors (sTie2/VEGFR-1) correlate with disease activity markers and functionnal magnetic resonance imaging parameters in multiple myeloma. Blood 2001 ; 98 : 301.
18. Blancher C, Moore JW, Robertson N, et al. Effects of ras and von Hippel lindau (VHL) gene mutations on hypoxia inducible factor (HIF)-1alpha, HIF2 alpha and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3 kinase/Akt signaling pathway. Cancer Res 2001 ; 61 : 7349-55.
19. Arbiser JL, Petros J, Klafter R, et al. Reactive oxygen generated by Nox 1 triggers the angiogenic switch. Proc Natl Acad Sci USA 2002 ; 99 : 715-20.
20. Schreiber S, Ackermann J, Obermaier A, et al. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br J Haematol 2000 ; 110 : 605-9.
21. Tai YT, Podar K, Gupta D, et al. CD40 activation induces p53 dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002 ; 99 : 1419-27.
22. Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathway is essential to induce long term remission xenotransplanted human leukemia. Proc Natl Acad Sci USA 2001 ; 98 : 10857-62.
23. Nowicki M, Ostalska-Nowicka D, Kaczmarek E, et al. Vascular endothelial growth factor C a potent risk factor in childhood acute lymphoblastic leukaemia : an immunocytochemical approach. Histopathology 2006 ; 49 : 170-7.
24. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF-C) signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002 ; 99 : 2179-84.
25. Korkolopoulou P, Apostodilou E, Pavlopoulos PM, et al. Prognostic evaluation of the microvascular network in myelodysplasic syndromes. Fortschr Roentgenstr 2002 ; 174 : 164-9.
26. Lai R, Estey E, Shen Y, et al. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 2002 ; 94 : 14-7.
27. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999 ; 94 : 3717-21.
28. Dias S, Choy M, Alitato K, et al. Vascular endothelial growth factor (VEGF-C) signaling thtough FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival and resistance to chemotherapy. Blood 2002 ; 99 : 2179-84.
29. Loges S, Heil G, Bruweleit M, et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independant prognostic factor for overall survival. J Clin Oncol 2005 ; 23 : 1109-17.
30. Kreuter M, Woelke K, Bieker R, et al. Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia 2006 ; 20 : 1950-4.
31. Faderi S, Do KA, Johnson MM, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 2005 ; 106 : 4303-7.
32. Fragoso R, Pereira T, Wu Y, et al. VEGFR-1 (FLT-1) acrivation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 2006 ; 107 : 1608-16.
33. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994 ; 87 : 503-8.
34. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000 ; 6 : 3111-6.
35. De Raeve HR, Vanderkerken K. The role of the bone marrow microenvironment in multiple myeloma. Histo Histopathol 2005 ; 20 : 1227-50.
36. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin 6 in paracrine tumor stromal cell interactions in multiple myeloma. Blood 2000 ; 95 : 2630-6.
37. Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology : control of tumor cell survival, growth, and bone cell differentiation. Blood 1998 ; 91 : 2679-88.
38. Colla S, Morandi F, Lazzaretti M, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005 ; 19 : 2166-76.
39. Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma : production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2 and induction of MMP-1 by myeloma cells. Blood 1997 ; 90 : 1649-55.
40. Braunstein M. Circulating endothelial progenitor cells in multiple myeloma : implications and significance. Blood 2005 ; 105 : 171-6.
41. Andersen NF, Standal T, Nielsen JL, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma : correlation with bone marrow angiogenesis and survival. Br J Haematol 2001 ; 66 : 83-8.
42. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2001 ; 105 : 1383-95.
43. Aref S, Mabed M, Zalata K, et al. The interplay between c-Myc oncogene expression and circulating vascular endothelial growrh factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL) : relationship to patient outcome. Leuk Lymphoma 2004 ; 45 : 499-506.
44. Wang ES, Teruya-Feldstein J, Wu Y, et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004 ; 104 : 2893-902.
45. Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor : a is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T cell lymphoma and related to lymphoma progression. Lab Invest 2004 ; 84 : 1512-9.
46. Ruan J, Hyjek E, Kermani P, et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res 2006 ; 19 : 5622-31.
47. Steubel B, Choot A, Huber D, et al. Lymphoma specific genetic aberrations in microvascular endothelial cells in B cell lymphoma. N Engl J Med 2004 ; 351 : 250-9.
48. Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma : safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006 ; 6 : 998-1005.
49. Korkopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin's lymphoma : a morphometric approach in 286 patients with prognostic implications. Leukemia 2005 ; 19 : 894-900.
50. Bairey O, Boycov O, Kaganovsky E, et al. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004 ; 28 : 243-8.
51. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005 ; 19 : 524-30.
52. Lee YK, Shanafelt TD, Bone ND, et al. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3 : implication for apoptosis resistance. Leukemia 2005 ; 19 : 513-23.